Logo
x

Search

Subscribe Now

Taiho

Taiho’s Lonsurf (trifluridine/tipiracil) + Bevacizumab Receives EC’s Approval as 3L Treatment of Refractory Metastatic Colorectal Cancer

Taiho’s Lonsurf (trifluridine/tipiracil) + Bevacizumab Receives EC’s Approval as 3L Treatment of Refractory Metastatic Colorectal...

  • August 1, 2023
Taiho’s Lytgobi (futibatinib) Receives the US FDA’s Approval for the Treatment of Intrahepatic Cholangiocarcinoma

Taiho’s Lytgobi (futibatinib) Receives the US FDA’s Approval for the Treatment of Intrahepatic Cholangiocarcinoma

  • September 30, 2022
Taiho Entered into an Agreement to Acquire Cullinan for CLN-081/TAS6417 to Treat EGFR Exon20 Non-Small Cell Lung Cancer

Taiho Entered into an Agreement to Acquire Cullinan for CLN-081/TAS6417 to Treat EGFR Exon20 Non-Small Cell Lung Cancer

  • May 12, 2022
Taiho Exercised its Option to License Arcus’s Domvanalimab and AB308 for NSCLC in Japan and Other Countries

Taiho Exercised its Option to License Arcus’s Domvanalimab and AB308 for NSCLC in Japan and Other Countries

  • November 30, 2021
Top 20 Life Sciences Deals of 2020 by Total Deal Value

Top 20 Life Sciences Deals of 2020 by Total Deal Value

  • January 22, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.